Health
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
WILMINGTON, Del., October 18, 2025--Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual i
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/827aec8cc83d30cdf52ce556c3602547"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wNjc3bioYKTtXN4t0Cgoqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/827aec8cc83d30cdf52ce556c3602547","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_TZ7e8l1roYxaiKyGIRQ.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/827aec8cc83d30cdf52ce556c3602547","width":1024,"height":512}},"lazy":false},{"type":"text","content":"More than 92% of patients treated with AstraZeneca and Daiichi Sankyo’s ENHERTU were free of invasive disease at three years","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"DESTINY-Breast05 presented in ESMO Presidential Symposium alongside DESTINY-Breast11 reinforce potential for ENHERTU to become a foundational treatment in curative-intent early breast cancer setting","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., October 18, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment.","length":603,"tagName":"p"},{"type":"text","content":"Results showed ENHERTU significantly reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 as a post-neoadjuvant treatment (based on an IDFS hazard ratio [HR] of 0.47, 95% confidence interval [CI] 0.34-0.66, p<0.0001). At three years, 92.4% of patients in the ENHERTU arm were alive and free of invasive disease, compared with 83.7% of those in the T-DM1 arm. The IDFS results were consistent across all prespecified subgroups.","length":460,"tagName":"p"},{"type":"text","c...